A tale of two letters

We recently co-published an editorial stating that we and our sister journals would not publish tobacco-funded research.¹ There have been a number of responses.²³ Richard Smith² challenged us to explain why the same ban was not applied to Pharma-funded studies, given the degree of turpitude frequently clinging to that industry. The answer is that, whereas at least some of the actions of big Pharma, for example, in developing new medications, are wholly beneficial, this description can be applied to exactly none of the tobacco industry’s doings. So, we consider it reasonable to at least start from a position of giving a new Pharma study the benefit of the doubt and subject it to rigorous peer review. Another response was a self-righteous effusion from the chief scientific officer of BAT,³ praising the role that the ‘regulated tobacco industry’ can play. Since this ‘well-regulated industry’ makes the combined killing machines of all the 20th century dictators seem positively Heath Robinson, we can only respond in the words of Ira Gershwin in Porgy and Bess: ‘Friends with you, Low-Life? I fear I must decline!’ Were there any doubts as to the rightness of the BMJ’s policy, Proctor’s intervention³ would expunge them forthwith.

Andrew Bush,¹ Ian Pavord²
¹National Heart and Lung Institute, Imperial College, London, UK
²Nuffield Department of Medicine, University of Oxford, Oxford, UK

Correspondence to Prof Andrew Bush, National Heart and Lung Institute, Imperial College, London, SW3 6NP, UK; a.bush@imperial.ac.uk

Competing interests None.

Provenance and peer review Not commissioned; internally peer reviewed.

Received 6 January 2014
Accepted 6 January 2014
doi:10.1136/thoraxjnl-2014-205104

REFERENCES
2 Smith R. Arguments against publishing tobacco funded research also apply to drug industry funded research. Br Med J 2013;347:f6732.